Brought to you by:
The numbers are in: VAM 2023 adds up to another SVS classic
Landmark meeting (June 14-17) with nearly 1,400 vascular professionals moves the needle with program innovations, slew of new science and jam-packed agenda. With more content presented than ever before, a family-friendly Wednesday night gathering, the inaugural Frank J. Veith Distinguished…
Second edition of VSITE review text released
The second edition of a hit trainee-created textbook primarily aimed at those taking the Vascular Surgery In-Training Exam (VSITE) has hit the shelves. The Vascular Surgery Review Book, authored by Thomas Creeden, DO, a resident from the University of Massachusetts in Worcester,…
SVS seeks volunteers to write position paper
Society for Vascular Surgery (SVS) members have until July 31 to apply to serve on a new SVS writing group to develop a position paper on the scope of work of vascular surgery practice in diagnosing and treating vascular disease.…
Study finds similar rates of VTE in both flying and non-flying surgical patients
Uncertainty underlying the magnitude of risk posed by long distance air travel in venous thromboembolism (VTE) patients has created the need for a deeper, systematic dive into the guidelines and resources providers should be turning to when managing their pre-flight…
Long-awaited FDA update finds data do not support excess mortality risk for paclitaxel-coated devices
[vc_row][vc_column][vc_column_text] In a letter to healthcare providers dated July 11, 2023, the Food and Drug Administration (FDA) communicates that the risk of mortality associated with paclitaxel-coated devices to treat peripheral arterial disease (PAD) is no longer supported based on data…
VESAP5 expires July 14
The SVS’ fifth edition of the Vascular Education and Self- Assessment Program (VESAP5) expires at 9 a.m. CDT July 14 and with it, the possibility of claiming continuing medical education credits. Learners can earn credits and obtain certificates until then.…
Review urges development of protocols to reduce hypersensitivity reactions after cyanoacrylate varicose vein treatment
Despite being considered “generally safe,” cyanoacrylate can cause local reactions in up to 25% of patients, disproportionately affecting women, Asian race and thin patients with a body mass index of <22. This was the conclusion drawn by Eduardo Silva, MD,…
The top 10 most popular Vascular Specialist stories of June 2023
Last month, Vascular Specialist garnered readers’ attention with an array of commentary on the BEST-CLI and BASIL-2 trials; the medical editor’s interview with vascular surgery’s ‘living legend’ Frank J. Veith, MD; the news of the death of Past SVS President…
Surmodics receives FDA approval for the SurVeil drug-coated balloon
Surmodics has announced the receipt of Food and Drug Administration (FDA) approval for the SurVeil drug-coated balloon (DCB). A company press release notes that the SurVeil DCB may now be marketed and sold in the U.S. to physicians for percutaneous…
FDA approves study of ZFEN+ for treatment of aortic aneurysms
The Food and Drug Administration (FDA) has granted approval for Cook Medical to initiate an investigational device exemption (IDE) study on the Zenith fenestrated+ endovascular graft (ZFEN+). The clinical study will assess the safety and effectiveness of the ZFEN+ in…